HDDC2 Promotes HCC Progression Associated with AKT/mTOR/S6K1 Signaling
Journal of Hepatocellular Carcinoma · 2026-11 · Volume 13 · 1-19
DOI: 10.2147/jhc.s639829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-11. Verfasst von Lingling Mo und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Aims
To investigate the expression of HDDC2 in hepatocellular carcinoma (HCC) and its impact on patient prognosis, as well as to analyze its biological functions and potential molecular correlations in HCC. Materials and Methods: The role of HDDC2 in HCC was preliminarily explored through bioinformatics analysis. RT-qPCR and Western blot were used to measure HDDC2 expression in hepatoma cell lines and normal liver cells. HDDC2 knockdown and overexpression cell models were established to evaluate its effects on cell proliferation, migration, and invasion. A nude mouse xenograft model was constructed to monitor tumor growth dynamically and conduct immunohistochemical analyses. Proteomic analysis and Western blot were used to explore the signaling pathways correlated with HDDC2.
Results
HDDC2 was highly expressed in HCC tissues and cell lines and was significantly associated with poor prognosis. HDDC2 promoted proliferation, migration, and invasion of hepatoma cells, while knockdown inhibited tumor growth and reduced Ki-67 expression. Proteomic and Western blot analyses indicated that HDDC2-mediated HCC progression is associated with alterations in the AKT/mTOR/S6K1 signaling pathway.
Conclusion
High HDDC2 expression correlates with poor prognosis in HCC patients and promotes tumor cell biological functions, this oncogenic effect is potentially linked to activation of the AKT/mTOR/S6K1 pathway. HDDC2 may serve as a potential prognostic biomarker for HCC. Though its prognostic association was observed only after adjustment for a limited set of covariates in our multivariate Cox model. Keywords: HCC, HDDC2, akt/mtor/s6k1 signaling, ki-67
Zitieren
APA
Mo, L., Wang, J., Wu, X., Li, X., Pan, L., Chen, X., & Chen, C. (2026). HDDC2 Promotes HCC Progression Associated with AKT/mTOR/S6K1 Signaling. Journal of Hepatocellular Carcinoma, Volume 13, 1-19. https://doi.org/10.2147/jhc.s639829
Vancouver
Mo L, Wang J, Wu X, Li X, Pan L, Chen X, et al. HDDC2 Promotes HCC Progression Associated with AKT/mTOR/S6K1 Signaling. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-19. doi:10.2147/jhc.s639829
BibTeX
@article{Mo2026,
author = {Mo, Lingling and Wang, Jingyi and Wu, Xinyue and Li, Xiangshen and Pan, Li and Chen, Xinxin and Chen, Chuang},
title = {HDDC2 Promotes HCC Progression Associated with AKT/mTOR/S6K1 Signaling},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--19},
doi = {10.2147/jhc.s639829}
}
EUVIMED